title: A fixed-dose 24-hour regimen of artesunate plus sulfamethoxypyrazine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan.
abstract: BACKGROUND
  Artemisinin-based combination therapy is increasingly being adopted as first-line antimalarial therapy. The choice of appropriate therapy depends on efficacy, cost, side effects, and simplicity of administration.
  
  
  METHODS
  the efficacy of fixed co-formulated (f) artesunate-sulfamethoxypyrazine-pyrimethamine (AS+SMP f) administered at time intervals of 12 hours for a 24-hour therapy was compared with the efficacy of the same drug given as a loose combination (AS+SMP l) with a dose interval of 24 hours for 3 days for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan.
  
  
  RESULTS
  seventy-three patients (39 and 34 in the fixed and the loose regimen of AS+SMP respectively) completed the 28-days of follow-up. On day 3; all patients in both groups were a parasitaemic but one patient in the fixed group of AS+SMP f was still febrile. Polymerase chain reaction genotyping adjusted cure rates on day 28 were 92.3% and 97.1% (P > 0.05) for the fixed and loose combination of AS+SMP respectively. Three (4.1%) patients (one in the fixed and two patients in the loose group of AS+SMP) in the study suffered drug-related adverse effects. Gametocytaemia was not detected during follow-up in any of the patients.
  
  
  CONCLUSIONS
  both regimens of AS+SMP were effective and safe for the treatment of uncomplicated P. falciparum malaria in eastern Sudan. Due to its simplicity, the fixed dose one-day treatment regimen may improve compliance and therefore may be the preferred choice.
authors.affiliation: Faculty of Medicine, University of Khartoum, Sudan. ishagadamm@Yahoo.com
authors.forename: Ishag
authors.initials: I
authors.lastname: Adam
authors.forename: Mamoun
authors.initials: M
authors.lastname: Magzoub
authors.forename: Maha E
authors.initials: ME
authors.lastname: Osman
authors.forename: Insaf F
authors.initials: IF
authors.lastname: Khalil
authors.forename: Michael
authors.initials: M
authors.lastname: Alifrangis
authors.forename: Khalid A
authors.initials: KA
authors.lastname: Elmardi
mesh_terms: D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use*; D037621:Artemisinins / Q000008:administration & dosage / Q000627:therapeutic use*; D000077332:Artesunate; D002648:Child; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005838:Genotype; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D018579:Patient Selection; D010963:Plasmodium falciparum / Q000235:genetics / Q000302:isolation & purification; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D012717:Sesquiterpenes / Q000008:administration & dosage / Q000627:therapeutic use*; D013397:Sudan; D013415:Sulfalene / Q000008:administration & dosage / Q000627:therapeutic use*; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D012717:Sesquiterpenes; D000077332:Artesunate; D013415:Sulfalene; D011739:Pyrimethamine